Home  |  News  | Member Log In  
 

Mission

The New England Healthcare Institute is dedicated to transforming health care for the benefit of patients and their families.

Who we are

NEHI is a nonprofit, health policy institute focused on enabling innovation that will improve health care quality and lower health care costs. Working in partnership with members from across the health care system, NEHI brings an objective, collaborative and fresh voice to health policy. We combine the collective vision of our diverse membership and our independent, evidence-based research to move ideas into action.

How we’re different

NEHI is not a trade organization or typical think tank. We represent all sectors of health care and use our research to move ideas into action. As an independent, coalition-building entity, we find mutual solutions to mutual problems facing health care. We are the largest, most diverse, multi-stakeholder health care organization in the nation.

Innovators in Health Awards

Submit your nominations for the 2010 Innovators in Health Awards here.

Visit the press room to review our media kit.

Learn how to become a member or support NEHI programs in other ways.

Board of Directors

Joshua Boger, PhD (Chair)

Founder & Chief Executive Officer (retired), Vertex Pharmaceuticals, Inc.

Joshua Boger is the founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and retired as CEO in May 2009. Prior to founding Vertex in 1989, he worked for more than a decade in pharmaceutical research at Merck, where he developed an international reputation as a leader in the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs. He holds a bachelor of arts in Chemistry and Philosophy from Wesleyan University (Connecticut) and a master's and doctorate degrees in Chemistry from Harvard University. He is the author of over 50 scientific publications, holds 31 issued U.S. patents in pharmaceutical discovery and development, and has lectured widely in the United States, in Europe and in Asia on various aspects of drug discovery, development and commercialization.

He is the Chairman of the New England Healthcare Institute, Chairman of the Board of Trustees at Wesleyan University (Middletown, CT), Vice-Chair of the Board of Fellows of the Harvard Medical School, Co-Chairman of the Progressive Business Leaders Network (a non-profit, non-partisan business organization) and Chair of the Board of the Celebrity Series (Boston’s premier performing arts series).

He serves on several additional Boards including the Biotechnology Industry Organization (BIO, where he is Immediate-Past-Chairman), the Harvard Board of Overseers, The Hastings Center (the leading independent bioethics research institute, located in Garrison, NY), the American Civil Liberties Union of Massachusetts Foundation, the Science Advisory Council of WGBH (public broadcasting’s leading station, Boston), the Museum of Science (Boston), the Massachusetts Workforce Investment Board, the Massachusetts Life Sciences Center, the Dean’s Advisory Group of the Harvard School of Engineering and Applied Sciences, the Harvard College Overseers’ Committee to Visit the Business School and the MIT Corporation Visiting Committees to the Department of Biology and to Whitaker College/Health Sciences & Technology (HST).

Joseph B. Martin, MD, PhD (Chair Emeritus)

Lefler Professor of Neurobiology and Dean Emeritus, Harvard Medical School

Joseph B. Martin, M.D., Ph.D. was appointed the Edward R. and Anne G. Lefler Professor of Neurobiology at Harvard Medical School in July 2007.

Prior to this appointment, Dr. Martin served for ten years as Dean of the Faculty of Medicine at Harvard University. At Harvard, he helped establish, in 1999, the Dana-Farber/Harvard Cancer Center, and in 2001, with the support of an anonymous donor, Dr. Martin formed the Harvard center for Neurodegeneration and Repair, dedicated to understanding the prevention, causes, and treatment of neurodegenerative diseases. In 2003, Dr. Martin dedicated Harvard Medical School's New Research Building, which is designed to cultivate scientific collaboration between the basic and clinical sciences.

From 1989-1993 Dr. Martin served for four years as Dean of the School of Medicine at UCSF. During his tenure as Dean, he established the W.M. Keck Foundation Center for Integrative Neurosciences, the Gladstone Institute for Virology and Immunology, and began planning for a Comprehensive Cancer Center. In 1993, he was appointed Chancellor of UCSF.

Dr. Martin served on the Faculty of Medicine at McGill University in Montreal from 1970-1978. Following his tenure at McGill, he was chief of the Neurology Service at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at HMS from 1978-1989. At the Massachusetts General Hospital, he led the development in neurogenetics of neurodegenerative disorders, leading to the discovery of the gene for HD.

Dr. Martin received his premedical and medical education at the University of Alberta, Edmonton, earning the M.D. degree in 1962. He completed a residency in neurology in 1966 and fellowship in neuropathology in 1967 at Case Western Reserve University in Cleveland, Ohio, and received his Ph.D. in anatomy from the University of Rochester in 1971.

Henri Termeer (Chair Emeritus)

Chairman & Chief Executive Officer, Genzyme Corporation

Henri A. Termeer was appointed president of Genzyme Corporation in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. Under his leadership, Genzyme has grown from a modest entrepreneurial venture to one of the world's leading biotechnology companies, and in 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Mr. Termeer is recognized as a pioneer in developing and delivering treatments to patients with rare genetic diseases around the world. He is a trustee for the Boston Museum of Science, a member of the Massachusetts Institute of Technology Corporation and a member of the board of directors of Project HOPE, an international nonprofit health education and humanitarian assistance organization.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer serves on the board of directors of both the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. He is a director of Massachusetts General Hospital and is a member of the board of fellows of Harvard Medical School. In addition, Mr. Termeer is deputy chairman of the Federal Reserve Bank of Boston's board of directors and a member of the board of directors of Abiomed Inc. He was also instrumental in founding the New England Healthcare Institute.

A Native of the Netherlands, Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.

Burt Adelman, MD (Vice Chair)

Lecturer in Medicine, Harvard Medical School

Burt A. Adelman, M.D. was previously Executive Vice President, Research and Development at Biogen, a position he attained in October 2001. Prior to that time, Dr. Adelman was Vice President of Medical Research. He began his career with Biogen in 1991, joining the company as Director of Medical Research, and has held positions of increasing responsibility including Vice President, Regulatory Affairs, and Vice President, Development Operations. In that role he oversaw the Preclinical Development, Medical Operations and Regulatory Affairs groups. Since 1992, Dr. Adelman has served as a lecturer at Harvard Medical School. He is a member of the Board of Directors for the New England Healthcare Institute (NEHI).

Harris A. Berman, MD (Vice Chair)

Vice Dean, Tufts University School of Medicine

Harris A. Berman, MD is vice dean at the Tufts University School of Medicine. Prior to his current role, he was a pioneer in the development of managed care in New England, and for 17 years, the CEO of the Tufts Health Plan. During that tenure, Tufts Health Plan grew from 60,000 to over a million members.

Before joining Tufts Health Plan, Dr. Berman co-founded the Matthew Thornton Health Plan in Nashua, NH, one of the first HMOs in New England. He served initially as the HMO’s Medical Director beginning in 1971, then as its Executive Director. He has served as chairman of the Massachusetts Association of HMOs, chairman of Affiliated Health Information Networks of New England, a director of the American Association of Health Plans, and is still Chairman of the Board of the Bank of America Celebrity Series and a member of the Board of Directors of the New England Medical Center, AvMed Health Plan of Florida, and Hebrew Senior Life. Dr. Berman recently became Chairman of the Board of the Massachusetts Health Quality Partners. In addition, Dr. Berman has international experience as a Peace Corps Physician and a consultant to the U.S. Agency for International Development in several international projects.

A graduate of Harvard College and Columbia University College of Physicians and Surgeons, Dr. Berman served as a resident on the Harvard Medical Service of Boston City Hospital and at Tufts-New England Medical Center, and an Infectious Disease fellowship at Tufts-New England Medical Center. He is a fellow of the American College of Physicians.

Nick Littlefield (Vice Chair)

Partner, Foley Hoag, LLP

Nick Littlefield, Partner and Co-Chair, Government Strategies Group, at Foley Hoag LLP, concentrates his practice in the areas of biotechnology, biomedical research and health care technology. He specializes in regulatory, administrative and legislative issues for large and small companies, non profit organizations and trade associations. Mr. Littlefield and his colleagues in the Foley Hoag Life Sciences Group work from offices in Boston and Washington. For nine years until 1998, Mr. Littlefield served as Staff Director and Chief Counsel for Massachusetts Senator Edward M. Kennedy on the United States Senate Health, Education, Labor and Pensions Committee, where he worked extensively on biomedical research, health policy, and life sciences regulatory and legislative initiatives. Previously, he taught at Harvard Law School and was an Assistant United States Attorney in the Southern District of New York. He is a graduate of Harvard College and the University of Pennsylvania Law School.

John Fallon, MD (Clerk)

Chief Physician Executive, Blue Cross Blue Shield of Massachusetts

Dr. Fallon oversees the Blue Cross Blue Shield of Massachusetts’ medical policies, acts as the main liaison with the plan’s provider network, reviews upcoming legislation for medical impact, manages the company’s medical directors, acts as primary spokesperson for medical inquires and main medical contact with Blue Cross Blue Shield Association and its 39 plans.

Dr. Fallon practiced Internal Medicine for over 20 years. Additionally, he was previously CEO for the entire clinical enterprise at the State University of New York’s Downstate Medical Center, Chairman of the physician network for Partners Healthcare System, and the founder and CEO of North Shore Health System, a physician-hospital organization involving more than 350 physicians and the North Shore Medical Center.

He serves on many boards locally, including the Neighborhood Health Plan and the New England Healthcare Institute, as well as nationally, the NCQA Medical Standards, and Temple University School of Medicine Board of Advisors.

Dr. Fallon received a Bachelor’s degree from the College of the Holy Cross, his Master’s degree in Business Administration from the University of South Florida, his M.D. from Tufts Medical School in Boston. He is Board Certified in Internal Medicine and is a Fellow of the American College of Physicians.

Beverly Lorell, MD (Vice Chair)

Senior Medical and Policy Advisor, King & Spalding, LLP

Beverly H. Lorell, M.D. is the Senior Medical and Policy Advisor with King & Spalding's FDA/Healthcare Practice Group in Washington, D.C. Dr. Lorell specializes in the areas of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. She also specializes in the area of physician and industry relations and the development of independent scientific panels to advise health industries.

Dr. Lorell, who was previously Professor of Medicine at Harvard University, has over twenty-five years of experience as a practicing interventional cardiologist and heart failure specialist. She is an internationally recognized clinical and basic science investigator with extensive experience in multi-center clinical trials and preclinical proof-of-concept translational science. Prior to joining King & Spalding, Dr. Lorell served as Vice President and global Chief Medical and Technology Officer at Guidant Corporation. There her responsibilities included evaluating emerging technologies and attendant regulatory challenges, determining product development priorities, and influencing clinical research strategies. She participated in the firm's board for business development.

During her career at Harvard Medical School, she served the federal government in multiple roles including as a federally funded investigator of the National Institutes of Health and on the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee.

Dr. Lorell has served in national leadership positions in professional societies. She was an Established Investigator of the American Heart Association (AHA). Additional honors include election as Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA) and founding member of the Heart Failure Society of America. She served on the Executive Committees of both the Council on Clinical Cardiology and the Council on Basic Science of the AHA. Recent national leadership roles included the national Executive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians, a body which determines national standards for medical competency for novel cardiovascular technologies. She was also a member of the Consensus Conference Group on Professionalism and Ethics of the ACC and AHA. She continues to be an active invited lecturer at national professional meetings, as well as Harvard Law School and Harvard Medical School.

Dr. Lorell is a graduate of Stanford University, and she received her M.D. degree and her Residency in Internal Medicine from Stanford University Medical School. She received her advanced training as a Fellow in Cardiovascular Medicine at Harvard University. She is a Diplomate of the American Board of Internal Medicine, the Subspecialty Board of Cardiovascular Disease, and the Subspecialty Board of Interventional Cardiology. She is admitted to practice medicine in the states of California and Massachusetts. She is the author of over 160 medical science publications, 26 chapters and 2 books, including 8 recent publications in the area of health policy.

Jonathan Fleming (Treasurer)

Managing Partner, Oxford Bioscience Partners

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.

Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.

Mr. Fleming is a co-founder and Chairman of the Board of Memory Pharmaceuticals (NASDAQ: MEMY). He is also Chairman of the Board of BioProcessors Corporation and is a director of several private companies including Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer at the MIT Sloan School of Business.

Joel W. Beetsch, PhD

Senior Director, U.S. Advocacy and Corporate Affairs, sanofi-aventis

Joel Beetsch currently holds a position in U.S. Strategic Advocacy within the sanofi-aventis Corporate Affairs department. In this position, Dr. Beetsch leads the development and execution of a coordinated advocacy strategy working with multiple patient, provider, and payer organizations to foster safe and effective solutions to healthcare problems. Dr. Beetsch also provides senior counsel and expert recommendations to support executive management in establishing a coordinated and effective strategy for market-shaping efforts.

In his twelve years in the pharmaceutical industry, Dr. Beetsch has held several Medical and Corporate Affairs positions and has been with sanofi-aventis for five years.

Joel has professional interests in patient-focused care coordination, health policy, and the use of health information technology. Dr. Beetsch’s scientific interests include the physiologic and pathophysiologic mechanisms of metabolic disorders such as atherosclerosis, thrombosis, hypertension, and diabetes. Dr. Beetsch has written various peer-reviewed publications and abstracts in these scientific areas.

Joel earned his Doctorate in Neurobiology/Biochemistry from the Wright State University School of Medicine. Following his doctorate work, Dr. Beetsch was further trained in neurobiology at the Washington University School of Medicine in St. Louis.

Michael F. Collins, MD

Chancellor, University of Massachusetts Medical School

Michael F. Collins, MD, a nationally respected education and health care policy advocate and leader of not for profit health care, was appointed Senior Vice President for Health Sciences at the University of Massachusetts and interim Chancellor of the University of Massachusetts Medical School in June of 2007.

Dr. Collins currently directs the University of Massachusetts system-wide health sciences efforts, charged with leading strategic initiatives to further the university's efforts in the Commonwealth's critical life sciences industry. As interim chancellor of the medical school, Dr. Collins, a Clinical Professor of Medicine, provides critical direction and leadership to the campus' continuing efforts to distinguish itself as a premier academic health sciences center of national distinction. Dr. Collins directs the campus' external outreach, focusing on expanding and enhancing relationships with the University Board, the UMass Memorial Health System, the community, the legislature and the philanthropic community. In addition, he provides guidance for institutional advancement and fundraising initiatives and administrative oversight and leadership for UMass Medical School enterprise operations, including Commonwealth Medicine and the Massachusetts Biologics Laboratories. Dr. Collins is also responsible for managing the institutional infrastructure, including oversight of finance and campus operations.

Dr. Collins was appointed chancellor of the University of Massachusetts Boston in 2005. In this role, he was charged with overseeing an institution renowned for its access to excellence and its diversity. The most diverse university in New England, the campus boasts a student population of 13,000, speaking over 90 languages. Chancellor Collins managed a university budget of $225 million and led an academic community of more than 800 full and part-time faculty. In the two years Chancellor Collins led UMass Boston, he initiated campus efforts to complete a strategic and master planning effort to increase enrollment, research support and philanthropic giving to garner local and national recognition for the UMass Boston programs; and, began much needed physical improvements to the campus.

Prior to joining UMass Boston, Dr. Collins served as president and chief executive officer of Caritas Christi Health Care System from 1994 to 2004. Under his leadership, Caritas Christi became the second-largest healthcare system in New England, generating more than $1.1 billion in annual revenues from six acute care hospitals, physician group practices, several extended care facilities and other healthcare entities, all located in eastern Massachusetts. From 1994 to 2001, Dr. Collins also served as president of St. Elizabeth's Medical Center in Brighton, a university academic medical center affiliated with Tufts University School of Medicine.

Matthew D. Eyles

Vice President, Public Affairs and Policy, Coventry Health Care Inc.

Mr. Eyles is the Vice President, Public Affairs and Policy, for Coventry Health Care Inc. Previously, he was responsible for leading the Wyeth Public Policy department and the development of Wyeth public policy initiatives. The department works with public policy leaders inside and outside of government to shape the health policy agenda and related government decisions that will have an impact on the company and the research-based pharmaceutical industry. In addition, he plays a central role in managing the company' involvement in industry trade associations, such as the Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Industry Organization (BIO), and the National Pharmaceutical Council (NPC). He is also a member of the Wyeth U.S. Management Team.

Mr. Eyles joined Wyeth as Director, Federal Health Policy in 2001 from Eli Lilly and Company and has held several positions of increasing responsibility at Wyeth. Prior to his role at Lilly, he worked on Capitol Hill at the Congressional Budget Office (CBO) analyzing legislation reported by several committees of the U.S. House of Representatives and Senate.

Mr. Eyles has undergraduate degrees from The George Washington University in Political Science and History and earned an M.S. in Public Policy from the University of Rochester (NY).

Donald J. Gudaitis

Chief Executive Officer, American Cancer Society - New England Division

Donald J. Gudaitis became the first Chief Executive Officer of the American Cancer Society’s New England Division when the six New England states merged in 1997. For the previous decade, he served as the Executive Vice President of the Society’s Massachusetts Division. He currently leads or serves on numerous national-level American Cancer Society strategic teams.

Before coming to New England, Mr. Gudaitis served as the Executive Vice President for the American Cancer Society’s former Delaware Division for two years, and before that, as an Area Director for the former New Jersey Division. A graduate of Dickinson College with a major in psychology, he has completed the core M.B.A. program at Rutgers University. In 1993, Mr. Gudaitis was named one of the Ten Outstanding Young Leaders by the Boston Jaycees.

Roberta Herman, MD

Chief Operating Officer, Harvard Pilgrim Health Care

Dr. Herman is the Chief Medical Officer and SVP for Health Services at Harvard Pilgrim Health Care, a not-for-profit regional health plan serving over 1 million members in Massachusetts, NH and Maine. Harvard Pilgrim has been named the #1 commercial health plan in America according to a joint ranking by U.S. News & World Report and the National Committee for Quality Assurance (NCQA)* for three consecutive years.

Dr. Herman began her professional career at Harvard Community Health Plan in 1985 practicing Internal Medicine at the Cambridge Health Center. She taught and then directed the Quantitative Skills course for Harvard Medical Students in the New Pathway Program and subsequently served as an epidemiologic consultant in HCHP’s Deputy Medical Director’s Office. From 1992-1995, Dr. Herman served as Chief of Internal Medicine at the Cambridge Center.

Shortly after Harvard Community Health Plan’s merger with Pilgrim Health Care in 1995, Dr. Herman assumed the position of Associate Medical Director for Clinical Programs for Harvard Pilgrim Health Care (HPHC.) Her responsibilities included oversight and management of Technology Assessment, Clinical Guidelines, Health Promotion, Outreach and Disease Management Programs. In 1999, her role was expanded to include primary operational responsibility for the quality program and pharmacy. In 2000, she was promoted to V.P. and Medical Director for Network Management at Harvard Pilgrim Health Care adding to her portfolio oversight of HPHC’s vended contracts with for pharmacy and behavioral health and design and implementation of provider incentive programs. In 2001, Dr. Herman was appointed the health plan’s Chief Medical Officer. In July 2005, her role was expanded to the business functions related to managing Harvard Pilgrim’s network including contracting and provider relations.

Dr. Herman is a graduate of McGill University Medical School (Montreal, Canada). She completed her residency in Internal Medicine at the Royal Victoria Hospital (Montreal, Canada) and received a Masters equivalent degree in Epidemiology and Biostatistics from McGill University while doing a fellowship year in Community Medicine.

Kenneth Kaitin, PhD

Director and Professor of Medicine, Tufts Center for the Study of Drug Development, Tufts University

Dr. Kaitin has served as the Director of the Tufts Center for the Study of Drug Development since 1998. He is also a Professor of Medicine at Tufts University School of Medicine. Dr. Kaitin is an internationally recognized expert on the science of drug development. He publishes extensively on the factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review. He also testifies in Congress on drug development issues and is frequently quoted in the business and trade press on R&D trends in the research–based pharmaceutical industry.

Dr. Kaitin is a former president of the Drug Information Association and editor–in–chief of the Drug Information Journal. He received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.

Cato Laurencin, MD, PhD

Vice President for Health Affairs and Dean, School of Medicine, University of Connecticut

Dr. Cato Laurencin was appointed the new Vice President for Health Affairs and Dean, School of Medicine at the University of Connecticut Health Center in August 2008. He succeeds Dr. Peter Deckers, both in that role and as Board member with NEHI. Dr. Laurencin is a noted orthopaedic surgeon and a Fellow of both the American Academy of Orthopaedic Surgeons and the American Surgical Association.

Prior to joining UConn, Dr. Laurencin held the Lillian T. Pratt Distinguished Professor, Chair of the Department of Orthopaedic Surgery and Orthopaedic Surgeon-in-Chief at the University of Virginia Health System. In addition, he was designated as a University Professor at the University of Virginia and holds professorships in Biomedical Engineering and Chemical Engineering.

Dr. Laurencin earned his undergraduate degree in chemical engineering from Princeton University and his medical degree from Harvard Medical School, where he was a Magna Cum Laude graduate and the recipient of the Robinson Award for Excellence in Surgery. During medical school, he also earned his Ph.D. in biochemical engineering/biotechnology from MIT where he was a Hugh Hampton young scholar. Upon completion of his doctoral degrees, Dr. Laurencin joined the Harvard University Orthopaedic Surgery residency program, ultimately becoming chief resident in orthopaedic surgery at Beth Israel Hospital in Boston.

Among his many national responsibilities, Dr. Laurencin has been Speaker of the House of the National Medical Association, and currently serves as Chair of the Board of the National Medical Association’s W. Montague Cobb Health Institute. He has been a member of the National Institutes of Health National Advisory Council for Arthritis, Musculoskeletal and Skin Diseases and the National Science Advisory Board for the U.S. Food and Drug Administration. He currently sits on the National Science Foundation’s Engineering Directorate Advisory Committee. He is a member of the Institute of Medicine of the National Academy of Sciences.

John T. Mollen

Senior Vice President, Human Resources, EMC Corporation

Jack Mollen is Executive Vice President for Human Resources at EMC Corporation. With 2007 revenues of $13.2 billion and more than 37,000 employees, EMC is the world's leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value from their information. Mr. Mollen leads EMC's global Human Resources practice to assure the availability of world-class talent to drive business success. Since joinring EMC in September 1999, he has been an innovator in putting EMC at the forefront of influencing the health care marketplace to help control employee and company costs.

Mr. Mollen is a director of the Human Resources Policy Association and is also an advisory board member for Working Mother Magazine, which promotes opportunity for women in business. Prior to EMC, he was with Citigroup Inc., where he was Vice President of Human Resources for Citigroup's 80,000-person Global Operations and Technology organization. He played a key employee-integration role following the 1998 merger of Citicorp and Travelers Group, Inc. Before joining Citigroup, Mr. Mollen held a number of positions with Harris Corp., where as Vice President of Administration he was responsible for IS, Quality, Engineering Services, Human Resources, Mergers and Acquisitions, Facilities and Security for the company's 12,000-person Electronic Systems sector.

Mr. Mollen holds a degree in Economics from St. John Fisher College in Rochester, New York and a Master's degree in Labor Relations from St. Francis College in Pennsylvania.

James Mongan, MD

President & Chief Executive Officer, Partners HealthCare System

James J. Mongan, M.D., is the president and chief executive officer of Partners HealthCare, a position he assumed on January 1, 2003. He chairs the Commission on a High Performance Health System and is also professor of health care policy and professor of social medicine at Harvard Medical School. From 1996-2002, Dr. Mongan served as president of Massachusetts General Hospital (MGH), the largest and oldest teaching affiliate of Harvard Medical School. Before his tenure at MGH, he served for 15 years as executive director of the Truman Medical Center in Kansas City and as dean of the University of Missouri-Kansas City School of Medicine. Prior to that, he spent 11 years in Washington, DC. He served as a staff member of the Senate Committee on Finance for seven years, working on Medicare and Medicaid legislation, and he served in the Carter administration as deputy assistant secretary for health and then at the White House as associate director of the domestic policy staff.

Dr. Mongan is a member of the Institute of Medicine of the National Academy of Sciences. He chairs The Commonwealth Fund Health Care Reform Program Advisory Committee. He has served on the board of trustees of the American Hospital Association and the Kaiser Family Foundation, and was a member of the Prospective Payment Assessment Commission established by Congress. A native of San Francisco, Dr. Mongan received his undergraduate education at the University of California, Berkeley and Stanford University, and his medical degree from Stanford University Medical School. He completed his internship at Kaiser Foundation Hospital in San Francisco and served two years in the public health service.

Thomas J. Moore, MD

Associate Provost, Boston University Medical Center

Thomas J. Moore, MD is the Associate Provost for the Boston University Medical Campus and Director of the Office of Clinical Research at Boston University Medical Center. He is Professor of Medicine, Endocrinology and Nutrition at the BU School of Medicine, Co-director of the Master of Arts in Clinical Investigation program and the Medical School's liaison for the combined MD/MBA program.

Dr. Moore joined Boston University in 2001 and has since served in several leadership roles including Acting Provost for the BU Medical Campus in 2004-05 in addition to Acting Chairman of the Department of Medicine and Physician-in-Chief in 2005-06. Before joining the faculty of Boston University, he was a faculty member at Harvard Medical School and Physician at Brigham and Women's Hospital from 1977-2001. From 1995 till 2000, he was also Executive Medical Director with Merck and Co., Inc., directing Merck's medical and scientific affairs in the northeast US.

Dr. Moore is an expert in the area of nutrition and blood pressure. He is a fellow of the Council for High Blood Pressure Research of the American Heart Association and was named a Specialist in Clinical Hypertension by the American Society of Hypertension. He has served as an investigator of a Specialized Center of Research (SCOR) grant in Hypertension, a program project grant on aging, and was the Chairman of the Steering Committee of the DASH trial, an NIH-funded multi-center trial of nutritional approaches to stop hypertension.

Alan Moses, MD

Corporate Vice President and Global Chief Medical Officer, Novo Nordisk A/S

Alan Moses received a BS from Duke University and an MD from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, MO, the National Institutes of Health in Bethesda, MD, and Tufts-New England Medical Center in Boston.

Dr. Moses is board certified by the American Board of Internal Medicine and has subspecialty certification in Endocrinology and Metabolism. He is a Fellow of the American College of Physicians. In 1998, he was appointed Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center, a Harvard-affiliated independent clinical and research facility and was appointed to the rank of Professor of Medicine at Harvard Medical School in 2002. During his tenure at Harvard, Dr. Moses was involved in basic and clinical research, patient care, teaching of medical students, housestaff, and fellows, and medical research administration. He co-founded and co-directed the Clinical Investigator Training Program at Harvard Medical School and the Massachusetts Institute of Technology HST Program.

In April 2004, Dr. Moses joined Novo Nordisk, Inc as Associate Vice President for Clinical Research and Medical Affairs - Endocrinology and in 2007 was named Chief Medical Officer, North America. In January of 2008, he was named Corporate Vice President and Global Chief Medical Officer. In this role, he is involved in the full spectrum of the diabetes focus of Novo Nordisk from drug discovery, through drug development, brand messaging, and the implications of diabetes for the company and for patients, healthcare professionals and for healthcare systems.

He has written over 100 papers and articles on the treatment of diabetes, is an Editor of the Fourteenth edition of Joslin’s Diabetes Mellitus, and has been recognized both locally and nationally for clinical care in diabetes and for his research in diabetes and growth factors.

Samuel Nussbaum, MD

Executive Vice President and Chief Medical Officer, Wellpoint, Inc.

Dr. Samuel Nussbaum is executive vice president, clinical health policy and chief medical officer for WellPoint, Inc. He oversees corporate medical policy, clinical pharmacy programs, programs in clinical excellence, and health information technology. His principal responsibilities include: serving as chief spokesperson and policy advocate on medical issues, guiding the corporate vision regarding quality of care and its measurements, leading efforts to assess clinical quality performance and safety and developing a strategy to foster further collaboration with physicians and hospitals and national organizations (such as CDC and FDA) to strengthen and improve patient care. Dr. Nussbaum also has responsibility for HealthCore, WellPoint’s clinical outcomes research subsidiary.

Dr. Nussbaum has served as president of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, as Chair of America's Health Insurance Plan's (AHIP) Chief Medical Officer Leadership Council and as a member of the AHIP Board, and currently serves on the National Quality Forum (NQF) Board and on the Secretary of Health and Human Services Advisory Committee on Genetics, Health, and Society. He received the 2004 Physician Executive Award of Excellence from the American College of Physician Executives and Modern Physician magazine. Dr. Nussbaum is professor of clinical medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.

Dr. Nussbaum served as executive vice president, Medical Affairs and System Integration, of the BJC Health Care, where he led integrated clinical services across the health system and served as President of its medical group.

Dr. Nussbaum earned his medical degree from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University Medical Center and Massachusetts General Hospital and in endocrinology and metabolism at Harvard and Massachusetts General Hospital, where he directed the Endocrine Clinical Group. Dr. Nussbaum served as a professor at Harvard Medical School where his clinical and basic research has led to new therapies to treat skeletal disorders and new technologies to measure hormones in blood.

Joshua Ofman, MD

Vice President, Reimbursement and Payment Policy, Global Health Economics and Outcomes Research, Amgen Inc.

Joshua J. Ofman, MD, MSHS is the Vice President of Global Coverage & Reimbursement, Global Government Affairs and Vice President of Global Health Economics, Global Development. Dr. Ofman is Responsible for directing Amgen activities related to achieving coverage and reimbursement from National payers and oversight of evidence generation activities to demonstrate the economic value of Amgen products.

Dr. Ofman completed his undergraduate degree in the history and philosophy of science at University of California, Berkeley before completing his medical education at UC Irvine School of Medicine. He then completed his internship and residency in internal medicine at UCLA Medical Center. Following his residency, Dr. Ofman completed a two-year VA/UCLA/RAND fellowship in health services research, during which time he received his Masters of Science in Health Services (MSHS) degree from the UCLA School of Public Health. Dr. Ofman also completed a fellowship in gastroenterology at the UCLA integrated training program in digestive diseases. His research interests include health economics and technology assessment, program evaluation and health policy analysis, and he is widely published in these disciplines.

Dr. Ofman has served on several advisory boards for the American Gastroenterological Association, the American College of Physicians Clinical Efficacy Assessment Subcommittee, and is on the editorial board of the American Journal of Managed Care.

Prior to joining Amgen in 2003 as head of US Health Economics and Outcomes Research, Dr. Ofman was a member of the academic faculty in the Department of Medicine, UCLA School of Medicine, Cedars-Sinai Medical Center. Dr. Ofman also served as the Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.

Sandra Oliver

Vice President, Public Policy & State Government Affairs, Bayer HealthCare LLC

Sandra Oliver has more than 25 years experience in government affairs and sales management for two Fortune 500 companies with broad portfolios in Bio-Pharmaceuticals, Diagnostics and Chemicals. Ms. Oliver joined Bayer in June 2001 as Head of Public Policy and State Government Affairs for Bayer HealthCare LLC, and is responsible for developing and managing lobbying activities in 50 states on key public policy issues affecting Bayer’s Health Care companies. In 2006, she was promoted to Vice President, Public Policy and State Government Affairs.

Prior to joining Bayer, Ms. Oliver directed state government affairs for Hoffmann-La Roche, Inc. Her career in state government affairs was preceded by more than 17 years in the sales and marketing organization of Syntex Pharmaceuticals, first as a sales representative and ultimately as a regional sales director overseeing a sales force of more than 100.

Additionally, Ms. Oliver represents Bayer on key committees and Boards of the Pharmaceutical Research and Manufacturer’s Association, Biotechnology Industry Organization (BIO) and the Connecticut Business and Industry Association (CBIA). She is on the Board of Directors of the American Legislative Exchange Council and the Greater New Haven Chamber of Commerce.

In 2002, she was named Private Sector Member of the Year by the American Legislative Exchange Council. She has also been recognized by the YWCA of Bergen County, NJ Tribute to Women & Industry with the prestigious Twin Award. Ms. Oliver has a B.A. in Business Management from Eckerd College in St. Petersburg, Florida.

Andrin Oswald, MD

Chief Executive Officer, Novartis Vaccines and Diagnostics

Andrin Oswald, MD is CEO of Novartis Vaccines and Diagnostics, which was created from the acquisition of Chiron Corporation's vaccines and blood testing business. He is also a permanent attendee of the Executive Committee of Novartis.

Previously, Dr. Oswald was Chief Executive Officer of Speedel Holding AG and Global Head of Pharmaceutical Development Franchises in the Novartis Pharmaceuticals Division. Dr. Oswald joined Novartis in 2005 as Assistant to the Chairman and CEO. Before his appointment as Head of Development Franchises, he served as Head of the Country Pharma Organization (CPO) and Country President for Novartis in South Korea.

Dr. Oswald joined Novartis from McKinsey & Company, Switzerland, where he was an Associate Principal. Between 2002 and 2003 he was a Delegate of the International Committee of the Red Cross (ICRC) to Nepal.

He holds a doctorate in medicine from the University of Geneva.

Dean J. Paranicas

Vice President, Corporate Secretary and Public Policy, BD (Becton, Dickinson and Company)

Dean J. Paranicas is responsible for the Corporate Secretary function, and state and regional public policy activities.

Mr. Paranicas joined BD in 1981 and held various legal positions of increasing responsibility, becoming Associate General Counsel and Assistant Secretary. He later served as Director, Corporate Development and Strategic Investments, as Director, Investor Relations, and, most recently, as Vice President, Investor Relations and Public Affairs.

Mr. Paranicas began his career as an associate attorney with McCarter & English, LLP in Newark, New Jersey. He earned a B.A. degree With Honors from Rutgers College, Rutgers University, where he was a member of Phi Beta Kappa. He earned a J.D. degree from Rutgers-Newark School of Law, where he was an Editor of the Rutgers Law Review.

Mr. Paranicas is Secretary of the Healthcare Institute of New Jersey (HINJ) and Chair of HINJ’s Steering Committee. He also is Vice Chairman, Government Relations and a member of the Board of Trustees of the Foundation for New Jersey Public Broadcasting. He is a former member of the Rutgers University Board of Governors and the Rutgers University Foundation Board of Overseers. He is also a former chair of the Rutgers University Board of Trustees, where he is now a Trustee Emeritus.

Robert Perkins

Vice President, Policy & Promotional Affairs, AstraZeneca Pharmaceuticals LP

Robert W. Perkins is Vice President, Policy & Promotional Affairs at AstraZeneca Pharmaceuticals. In his role, Mr. Perkins is responsible for evaluating and assessing the impact of public policy forces and developing and reconciling strategic options to enhance the company’s image, presence, market penetration and reach, based on insights from internal and external analysis. In addition, he is responsible for the Promotional Regulatory Affairs and Operations departments for Policy, Legal and Scientific Affairs.

Mr. Perkins joined AstraZeneca after serving as the first Executive Director of Together Rx LLC from January 2003 – August 2004. He led operations, strategic planning and enrollment expansion efforts for the rapidly growing prescription savings program, which was established in 2002.
Prior to joining Together Rx, Mr. Perkins held senior positions in Government Affairs, Public Policy and Business Operations at DuPont Pharmaceuticals Co., including Senior Vice President of Public Policy, and Vice President of Government and Public Affairs and Pharmaceutical Administration. While at DuPont, he was twice the recipient of the Summit Award, the company’s highest honor, as well as the Work-Life Award for management ability.
From 1988 to 1993, Mr. Perkins was Chief Operating Officer at Richards, Layton & Finger, P.A., Delaware’s largest law firm. From 1981 to 1986, he served as Press Secretary and Chief of Staff for Delaware Governor Pierre S. du Pont IV and Governor Michael N. Castle.

A native of New Jersey, Mr. Perkins received a B.A. in English Literature from Lynchburg College in Lynchburg, Virginia, and completed the program for senior executives in local and state government at Harvard University’s John F. Kennedy School of Government.

He has been active in a number of professional and civic organizations, including the Board of Directors of Easter Seals of Delaware and the Delaware Public Policy Institute.

Brent Pawlecki, MD

Corporate Medical Director, Pitney Bowes Inc.

Brent Pawlecki, MD serves as the Corporate Medical Director for Pitney Bowes Inc., overseeing all health related issues and services of the organization, including the Pitney Bowes' award-winning corporate clinics and wellness programs, and the Disability/Workers Compensation Department. Dr. Pawlecki initially joined Pitney Bowes as Associate Medical Director in 1999, and has served as the Corporate Medical Director since 2007. In addition, he serves as the corporate medical consultant and as Chief HIPAA Privacy Officer. Dr. Pawlecki works closely with the Environmental Health and Safety team, as well as the Health Care Strategy Group and the Crisis Management Team to direct corporate health and productivity for the global organization. Currently, he is heading the efforts of Pitney Bowes and the National Business Group on Health on End of Life planning and serves as a board member for the Campaign for Public Health.

Dr. Pawlecki completed Undergraduate and Medical School at St. Louis University, St. Louis, Missouri. After finishing his residency in Internal Medicine and Pediatrics in Connecticut at Bridgeport Hospital/Yale University, Dr. Pawlecki worked in the Emergency Department. He entered private practice on Long Island, NY, serving as Medical Director of a multi-specialty group, and was instrumental in expanding the practice from one to five locations. He then began working as the Medical Director of Occupational Medicine for a public 70-site physician practice management group. Dr. Pawlecki initially joined Pitney Bowes as Associate Medical Director in 1999, and has served as the Corporate Medical Director since 2007.

He has completed the degree of Masters of Medical Management (MMM) at the University of Southern California’s Marshall School of Business. He is actively involved in numerous professional organizations, including the National Business Group on Health, New York Business Group on Health, and serves a Board member for the Campaign for Public Health.

Richard Pops

Chairman, President and CEO, Alkermes, Inc.

Mr. Pops became Chairman of Alkermes in April 2007. From 1991-2007, he served as Chief Executive Officer of Alkermes. Under his leadership, Alkermes grew from a privately held company with 25 employees to a publicly traded pharmaceutical company with more than 800 employees in multiple locations in the United States. Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; CombinatoRx, Inc.; Acceleron Pharma, Inc.; Sirtris Pharmaceuticals, Inc.; the Biotechnology Industry Organization (BIO); the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Harvard Medical School Board of Fellows.

Geralyn S. Ritter

Vice President, Global Public Policy & Corporate Responsibility, Merck & Co., Inc.

Geralyn S. Ritter is Vice President, Global Public Policy & Corporate Responsibility, at Merck & Co., Inc. in Whitehouse Station, New Jersey. She is responsible for worldwide public policy, government affairs and corporate responsibility matters, as well as leading Merck's philanthropic initiatives. Ms. Ritter also serves as President of The Merck Company Foundation.

Prior to joining Merck in 2008, Ms. Ritter was Senior Vice President for International Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA) in Washington, DC. At PhRMA, she was responsible for international public policy advocacy on behalf of the U.S. research-based pharmaceutical industry. Prior to assuming her policy leadership role at PhRMA, Ms. Ritter was Assistant General Counsel for international issues at the organization.

Prior to joining PhRMA, Ms. Ritter served as Trade Counsel at the Washington law firm of Covington & Burling, where she represented clients on international trade and intellectual property matters, as well as in international litigation and arbitration.

While in Washington, Ms. Ritter also served for three years as Associate General Counsel for intellectual property matters at the Office of the U.S. Trade Representative in the Executive Office of the President. At USTR, Ms. Ritter represented the United States in international trade negotiations and international dispute settlement matters. She represented the United States in the first intellectual property case filed by the United States under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) at the World Trade Organization in Geneva, as well as in the first such case filed against the United States.

Ms. Ritter received a Masters of Arts degree in International Studies from the School of Advanced International Studies (SAIS) at Johns Hopkins University. She received her law degree from the Stanford University School of Law in Palo Alto, California, and her undergraduate degree in economics and political science from Duke University in Durham, North Carolina.

James Roosevelt, Jr.

President & Chief Executive Officer, Tufts Health Plan

Mr. Roosevelt joined Tufts Health Plan in 1999 as senior vice president and general counsel and held that position until June 2005, when he became president and chief executive officer. As the general counsel, he presided over the legal department and the company's compliance, privacy and government relations functions.

Before joining Tufts Health Plan, Mr. Roosevelt was the associate commissioner for Retirement Policy for the Social Security Administration in Washington, D.C. He has also served as chief legal counsel for the Massachusetts Democratic Party and is co-chair of the Rules and By-laws Committee of the Democratic National Committee. Mr. Roosevelt spent 10 years as partner at Choate, Hall and Stewart in Boston. He is past chairman of the board of trustees for the Massachusetts Hospital Association, past president of the American Health Lawyers Association and past chairman of the board of trustees for Mount Auburn Hospital. Currently, Mr. Roosevelt serves as chairman of the board of directors for Massachusetts Association of Health Plans, and as a member of the board of directors at America’s Health Insurance Plans, Emmanuel College and the Kenneth B. Schwartz Center. He is also co-chair of the board of directors for the Tufts Health Care Institute. In November 2008, President-elect Barack Obama appointed Mr. Roosevelt to his transition team to co-chair a review of the Social Security Administration.

Mr. Roosevelt received his J.D. from Harvard Law School and his A.B. with honors in government from Harvard College. He has also completed the Advanced Management Program at Harvard Business School.

Eric Z. Silfen, MD

Senior Vice President and Chief Medical Officer, Philips Healthcare

Dr. Eric Z. Silfen is Senior Vice President and Chief Medical Officer for Philips Healthcare, located in Andover, Massachusetts. Prior to joining Philips Healthcare in 2008, he was Senior Director of the Department of Biomedical Informatics Research for Philips Research North America, where he has led the design, development, validation and evaluation of clinical decision support systems for biomedicine. Since joining Philips in 2006, Dr. Silfen has focused on healthcare research work in the areas of clinical bioinformatics, molecular medicine, computer-aided imaging, clinical systems, and diagnostic evaluations. In this role, he has worked closely with Philips Research teams, academics and researchers in North America and Europe.

Dr. Silfen’s clinical, academic, and hospital administration experience is extensive. He received his Doctor of Medicine from Georgetown University School of Medicine in Washington,DC, and completed residencies in Internal Medicine and Emergency Medicine at Georgetown University Hospital. He is Board certified in Internal Medicine and Emergency Medicine. Eric has held a broad range of medical posts, including Chief Medical Officer at St. Charles Hospital and Rehabilitation Center, Port Jefferson, NY, Chief Medical Officer for the Reston Hospital Center, Reston, Virginia, and as Medical Director for Emergency Medical Services, Metropolitan Washington Airport Authority, Dulles Airport, in Washington, DC.

Dr. Silfen is well-versed in healthcare administration issues. He has worked with the Hospital Corporation of America (HCA), a leading provider of healthcare services for more than 280 hospitals and outpatient centers in the United States and England. He has participated in the implementation of patient safety and medication error reduction initiatives and other hospital-wide programs focusing on clinician order entry, pharmacy and therapeutics policies and procedures, and physician leadership and education.

Dr. Silfen has built a broad network of colleagues in the global medical community and is well recognized for his career accomplishments and teaching experience. He has extensive experience in hospital and health plan clinical affairs, disease and care management programs, Joint Commission and National Committee for Quality Assurance standards and clinical quality/performance improvement. In addition, Dr. Silfen has expertise in the implementation of information technologies in the medical setting. He is also a member of numerous professional societies, including the Society for Critical Care Medicine, the Society for Medical Decision Making, the Health Information Management Systems Society, and The New York Academy of Sciences.

Dr. Silfen also holds a Master of Science in Healthcare Administration from Medical College of Virginia, and a Master of Arts in Biomedical Informatics from Columbia University in New York.

Eve Slater, MD, F.A.C.C.

Associate Clinical Professor of Medicine, Columbia University College of Physicians & Surgeons

Dr. Eve Slater is an Associate Clinical Professor of Medicine at Columbia University College of Physicians & Surgeons.

Dr. Slater’s career in medicine, science and public policy has spanned academics, business and government. Most recently she was Senior Vice President of Worldwide Policy at Pfizer, Inc., where she represented the pharmaceutical industry in healthcare reform with a special emphasis on coinsurance and medication adherence. She has served as Assistant Secretary of Health for the U.S. Department of Health and Human Services. Prior to joining HHS, she spent over 19 years with Merck in a number of critical scientific, strategy and public policy positions. In 1983, she joined the Merck Research Laboratories in biochemical endocrinology and molecular biology, and in 1988, she was promoted to head the regulatory affairs department as VP and later SVP of Clinical and Regulatory Development. In 2001, she was named as SVP of External Policy for Merck Research Laboratories, and VP of Merck Corporate Public Affairs. An expert on HIV treatment research, she served as a member of both the U.S. Keystone National Policy Dialogue on HIV and the NIH Office of AIDS Research Advisory Council. An expert on the FDA, she was named to the Subcommittee of the FDA Science Board in 2007.

In 2001, Dr. Slater was appointed by President George W. Bush as Assistant Secretary of Health, the first woman to hold this position. In this role, she served HHS Secretary Tommy Thompson as chief health policy advisor, with special emphasis on e-health and innovation, biosecurity, clinical subjects’ protection, women’s health, eldercare and HIV/AIDS. After leaving HHS, she became a director and advisor to a number of biotechnology companies, including Vertex Pharmaceuticals, Cambridge, MA and Phase Forward, Waltham, MA..

Dr. Slater received her B.A. from Vassar College and her M.D. from Columbia. She received her training in internal medicine and cardiology at the Massachusetts General Hospital, where she was the first woman named as Chief Resident in Medicine and later led the Hypertension Unit. She also served as Assistant Professor of Medicine at Harvard Medical School. A Fellow of the American College of Cardiology, she continues to serve patients as an Associate Attending Physician at NY Presbyterian Hospital and Associate Professor of Medicine at Columbia.

Lynn Taylor

Vice President, Government Affairs, EMD Serono Inc.

Lynn A. Taylor is Vice President of Government Affairs for EMD Serono, Inc. Ms. Taylor is responsible for all legislative, policy, and political activity for EMD Serono and for the oversight of the Washington, D.C. office. She is also responsible for building and solidifying relationships with key Federal and State government officials, policy makers and other key stakeholders for EMD Serono. Ms. Taylor guides the development of company positions related to key policy issues and legislation impacting the biopharmaceutical industry and EMD Serono’s business, products, policy and practices. She also serves as the chief liaison to major industry associations for the company, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Massachusetts Biotechnology Council (MBC). Ms. Taylor first joined the company in June 2005 as Executive Director of Government Relations.

Prior to joining EMD Serono, Ms. Taylor was Director, Federal Government Relations and Public Policy at Millennium Pharmaceuticals. Ms. Taylor also previously served as Director of Strategy and Health Policy at DEKA Research and Development and Director of Policy at PhRMA.

Ms. Taylor earned her master’s degree in public administration, with a concentration in policy analysis, from American University in Washington, D.C. and her bachelor’s degree in political science from Fordham University in New York.

David F. Torchiana, MD

Chairman & CEO, Massachusetts General Physicians Organization, Partners HealthCare System

In January 2003, Dr. Torchiana assumed the role of Chairman and Chief Executive Officer of the Massachusetts General Physicians Organization (MGPO). The MGPO, associated with the Massachusetts General Hospital, is a member of the Partners Health Care System and a teaching affiliate of the Harvard Medical School. The organization is a non-profit, tax-exempt corporation and the largest physician group practice in New England, representing more than 1,500 physicians.

Prior to his role at MPGO, Dr. Torchiana completed residencies in general surgery and cardiothoracic surgery at the MGH before joining the Department of Surgery there in 1989. He became Chief of Cardiac Surgery in 1998 and is an Associate Professor of Surgery at Harvard Medical School.

Dr. Torchiana graduated from Yale College in 1976. He spent the following year as a Churchill Scholar at Cambridge University, Cambridge UK, doing research in the Physiology Laboratory. He subsequently graduated from Harvard Medical School in 1981.

Josef H. von Rickenbach

Chairman & Chief Executive Officer, PAREXEL International, Inc.

As Chairman and CEO of PAREXEL, Mr. von Rickenbach has taken PAREXEL from its pioneering beginnings as one of the first clinical research organizations (CROs) more than two decades ago to its place as one of the top three public biopharmaceutical services companies today. He has led PAREXEL through its IPO, multiple public offerings, and over 30 acquisitions during the Company’s history of 28 years to expand its portfolio in order to meet changing client needs and market demand. Under his leadership, PAREXEL has evolved to provide a broad range of services to the biopharmaceutical industry, including integrated clinical development, regulatory affairs consulting, commercialization services and technologies that expedite time-to-market.

Foreseeing the globalization of clinical research, Mr. von Rickenbach has worked to expand PAREXEL’s global footprint to provide access to a wide array of geographies for clients’ programs. PAREXEL now operates in 70 locations throughout 54 countries, and has approximately 9,720 employees.

Mr. von Rickenbach has made several innovative contributions to the advancement of the biopharmaceutical services industry through PAREXEL, including conceiving of a complex, multi-disciplinary, systems-oriented approach to outsourced clinical development, bringing efficiencies, speed, scalability and standardization to the business. As part of the S-1 filing to the SEC, he was among the first to define the industry in formal terms. As the biopharmaceutical industry adopted information technology, Mr. von Rickenbach created a leading advanced technology offering, and today PAREXEL’s subsidiary Perceptive Informatics is a front runner in providing eClinical solutions.

Mr. von Rickenbach’s extensive experience in the biopharmaceutical services industries puts him at the forefront of drug development and management. After having begun his career with Schering-Plough, Mr. von Rickenbach also held positions with ENSECO (formerly ERCO).

Mr. von Rickenbach has served as Chair of the Association of Clinical Research Organizations (ACRO) and is a long-standing member of the ACRO Board of Directors. Mr. von Rickenbach is a key contributor to the New England business community, where PAREXEL’s global headquarters office is based. He serves on the Board of Directors of the New England Healthcare Institute and on the Health Policy and Management Executive Council of the Harvard School of Public Health. Mr. von Rickenbach previously won the Ernst & Young New England Entrepreneur of the Year Award, and has also served as a judge of the program.

Mr. von Rickenbach holds a B.S. degree in Business Economics from the School of Business at the Lucerne University of Applied Sciences in Switzerland, and a Master of Business Administration degree from Harvard University.

 
One Broadway, 12th Floor
Cambridge, MA 02142
phone icon  Phone:
(617) 225-0857
fax icon  Fax:
(617) 225-9025
email icon  Email:
info@nehi.net
Home   |   Directions   |   Contact Us   |   Privacy & Legal   |   RSS
© 2010 New England Healthcare Institute